Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Xenon ( (XENE) ).
On Feb. 26, 2026, Xenon Pharmaceuticals reported its fourth-quarter and full-year 2025 results, highlighting heavy investment in late-stage development of azetukalner across epilepsy and neuropsychiatric indications. The company is advancing multiple Phase 3 programs, including X-TOLE2 and X-TOLE3 in focal onset seizures, X-ACKT in primary generalized tonic-clonic seizures, and X-NOVA and X-CEED in depression and bipolar disorder, supported by 48‑month open-label data showing sustained seizure reduction and long-term safety.
Xenon is also progressing early-stage NaV1.7 and KV7 candidates XEN1701 and XEN1120 in Phase 1 pain studies and continuing IND-enabling work on a NaV1.1 program for Dravet syndrome, while its partnered NaV1.2/NaV1.6 inhibitor with Neurocrine remains in Phase 1. To fund this pipeline, the company raised $242.2 million via at-the-market equity sales, ending 2025 with $586 million in cash and pro forma liquidity of $716 million, which it expects will support operations into the second half of 2027 despite a 2025 net loss of $345.9 million driven by expanded R&D and higher operating costs.
The most recent analyst rating on (XENE) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
The score is driven primarily by weak financial performance (large losses and heavy cash burn), partially offset by an optimistic earnings-call outlook and runway guidance into 2027, plus supportive technical uptrend. Valuation remains constrained by negative earnings and lack of dividend support.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, clinical development and commercialization of ion-channel targeted therapeutics for neurological and psychiatric disorders. Its lead asset, azetukalner, a KV7 potassium channel opener, is in Phase 3 trials for epilepsy, major depressive disorder and bipolar depression, alongside early-stage potassium and sodium channel modulators for pain and genetic epilepsies.
Headquartered in Vancouver and Boston, Xenon targets high unmet-need indications such as focal onset and primary generalized tonic-clonic seizures, mood disorders and pain, and also partners with Neurocrine Biosciences on sodium channel inhibitors for epilepsy. The company is positioning azetukalner as the most advanced clinically validated potassium channel modulator in late-stage development, supported by long-term efficacy and safety data in epilepsy and proof-of-concept data in MDD.
Average Trading Volume: 856,653
Technical Sentiment Signal: Buy
Current Market Cap: $3.46B
For a thorough assessment of XENE stock, go to TipRanks’ Stock Analysis page.